FDA Approved VORAXAZE to Treat High Methotrexate Level

Food and Drug Administration (FDA) permitted the Voraxaze for healing patients from detriments of Methotrexate in bloodstreams. Methrotration is a chemotherapy drug which is usually thrown away by the body through kidneys. Kidneys may get fail due to higher consumption of methotrexate.

The enzyme Voraxaze showed minor quality in Methotrexate levels by smashing the medicine into a form that can be eliminated from the body. This enzyme is presumed to be a remedy for patient veins at once.

M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, Richard Pazdur, mention if continuous use of high levels of methotrexate may cause damage in liver, kidneys and intestine, serve mouth sores, skin rashes, and deaths due to low blood counts may occur. Voraxaze the new treatment for Cancer patients would help in lethal constant higher level of methotrexate.

The scientists also aimed at reducing methotrexate level below the threshold is considered as detrimental. Foreseeing the properties in tolerate of itself on span of 8 days.

From 22 patients, only 10 patients achieved to carry sufficient levels of methotrexate, while the rest were failed to accomplish the target. Voraxaze is answerable for eradicating around 95% of methotrexate.

Low blood pressure, flushing, headache, vomiting, nausea and abnormal sensations in patients were due side effects of Voraxaze. BTG International ruled the marketing of this drug.

FDA alarms on birth-control pills as a high risk of blood clot formation

The United States Food and Drug Administration (FDA)—“remains concerned” over certain contraceptive pills that includes “drospirenone” that might raise a high risk of blood clots.

     

During a drug safety announcement on the agencies webpage, in the preliminary study Food and Drug Administration (FDA), founded a result suggests an increase of 1.5-fold threat of blood clots in the women who use birth control pills containing Bayer, as compared to the users of other hormonal birth control pills.

Bayer best selling drug, generic Yasmin and generic Yaz includes “drospirenone” that is a sort of sex hormone in females known as progestin, also accessible in it generic form.

Food and Drug Administration (FDA), has still not reached to a conclusion, weather only these products have a high risk of developing blood clots over the other pills. FDA has set up a external board of medical experts to talk about the issue.

Nearly all the contraceptive pills include 2 types of hormones progestin and estrogen. Hence all the pills raise a risk of blood clots and contain a warning label.

But according to FDA there is contradicting information over the risk of blood clot; most probably it is linked with drospirenone. Apart from this, there are six other studies published over the blood clot risk. Like some have reported that the formation blood clot is due to the used of drospirenone in the pills where as some say, use of levonorgestrel in the birth control pills also have the same risk. Whereas the risk of blood-clots is less among those women who intake birth-control medicine, the Food and Drug Administration (FDA) suggests that women’s who aren't consuming these pills are at the higher risk.

FDA initiates to update New Guidelines to Improve Quality of Clinical Trials

Food and Drug Administration (FDA) has issued a guidance draft, to improve the clinical trial for researchers and manufacturers for a much superior quality check in support of premarket approval (PMA) request for medical plans.

This draft will include new guidelines regarding; new regulation, new guidance for development, upgrading FDA's internal quality check, Clinical Trial Transformation Initiative (CTTI) - require modernizing the clinical trial project, improving the training of the health authorities in context to inspection of the clinical check and modernization of regulation. FDA has also been improving its report on of violative inspection and functioning to recognize substitute methods to choose the clinical researcher for inspection.

The newly proposed guideline designed for clinical trial includes; setting proper study aims, reducing data bias, and choose a correct study site and participants. FDA has implemented total 25 action plans to strengthen the process, improve the certainty and transparency in the regulatory trial.

Food and Drug Administration (FDA) want to lend a helping hand to the manufacturers and the researchers, to manage a secure and an efficient product in the market without any burden.

This proposed guideline will help manufacturers and researchers for enhanced their understanding towards, FDA's vital expectations from clinical trials. FDA's is encouraging researchers to get in touch and discuss the most sensible move toward to studying their device."
generic viagra
Today these draft guidelines will help manufacturers and researchers to design a essential study related to their assets of effort, time, and capital so that they have high possibility of representing the security and the effectiveness of their product.

Vivus’s NDA accepted by FDA for Avanafil (and ED drug)

Vivus Inc. has declared that the U.S. Food and Drug Administration have accepted for review the company's new drug application or NDA. FDA would be reviewing Vivus Inc.’s investigational drug candidate called avanafil for treating the problem of erectile dysfunction in males. The company has also announced April 29, 2012 as the target date for the FDA to complete its review of the product’s NDA.

There has been a previously announced report of the phase 3 trials with the product avanafil that talks of results that it yielded. The report said that patients who were treated with avanafil saw noteworthy improvement in the erectile function as compared to placebo. A program called the avanafil development program was conducted that included over 1,350 patients and avanafil was displayed as one of the most tolerated and effective drug in treating patients with General ED and diabetics patients with ED. The company also said in its report that results observed in the phase 3 also confirmed by the long-term safety study.

News by Generic Viagra

Similar attitude will not work for 'Bio-Similars'- FDA

The Food and Drug Administration (FDA) of the United States has reworked on their thinking on biosimilar drugs recently, mentioning that due to their rigidity the “one size fits all” followed by them all these days will not work.

Instead, the agency’s scientists would weigh the array of information or the evidences in its entirety to judge the biosimilarity. According to the many chief FDA officials who have written in the Aug. 4 issue of the New England Journal of Medicine have designed a feasible approach to review and approval of biosimilars in the United States.

For several years now, Biotechnology and pharmaceutical companies have been noticing the decisions taken by the FDA very closely, as the market for biosimilars is claims to be really large. Talking local, the Momenta Pharmaceuticals Inc. of Cambridge has already entered into the development of biosimilars and Quintiles Transnational Corp., which is  based in North Carolina with offices in Cambridge, has already signed a deal of $266 million partnership with South Korea’s Samsung Group to produce biosimilars near the Seoul.

According to market studies, the world wide biosimilars market is expected to hit $19.4 billion by the year 2014 with a compound rate of 89.1 percent annual growth from 2009 to 2014. In the year 2008, Asia was the dominant market because it went into the commercialization of its products quite early. However, according to the researches conducted, the Americas will possibly in all likelihood dominate in 2014 triggered by U.S. market opening to the products in 2010.

After all this discussion, we must be clear about this thing called as ‘Biosimilars’. What is Biosimilars in the first place? Biosimilars are products that are similar to, (but not the same as), a new drug. Also known follow-on biologics, these products cost far less than an innovative drug. They treat patients who previously could not afford them with their new affordable treatment. These are not generic drugs that are considered to be the same as the brand. It is however official, but the journal article does signal towards the likelihood of its review applications for biosimilar products under the Biologics Price Competition and Innovation Act.

FDA and User Fee Act (for 2012)

Most of us know FDA is government body that regulates and monitors food and drug produced for commercial purpose. Its prime job is to evaluate safety of therapeutic products, be it food or medicine or cosmetic products. A question must have arisen in your mind, except those who are privy of internal matter, about where such a large agency gets fund to keep running. FDA is funded by two ways; one, money from tax payers; second, 'user fee' a fee paid by applicants.

There are two federal laws according to which FDA can take fee from manufacturers of drug or medical device. Every manufacturer has to acquire approval from FDA for their respective product. Producer can not bring their product in market without FDA approval.

PDUFA (Prescription Drug User Fee Act) and MDUFA (Medical Device User Fee Act) are the two laws which authorize FDA to take fee. The fee is only for use in CDER and CBER i.e. Center for drug evaluation research and Center for biologic evaluation research. FDA has to propose amendment if it wants increment in fee. Last time PDUFA was amended in 2007. Reauthorization for the year 2012 is being contemplated and final bill is likely be tabled in January for vote by Congress.

The law set a sort of benchmark for FDA. At the time of New Drug Application (NDA), FDA should ensure speedy approval of the 90% their new applications in 6 to 10 months. FDA has to meet this benchmark if it wants to continue fee collection. This condition is matter of concern for a part of community. Some people believe that while fullfiling the assurity, safety might get compromised.

Women birth control pills

FDA Proposed Guidance for Mobile Medical App

FDA has published guidelines for mobile medical application. This guidance would help FDA scrutinize more on software that claim to turn mobile instrument into medical device.

Purpose of the new guidelines is to address the concern of functionality of medical devices. In guideline FDA gave an example of differences in result of radiological image done with mobile of different screen size. These guidelines would eventually help accuracy of diagnosis. FDA has outlined various definitions of terms such as 'mobile medical application', 'mobile platform' and 'mobile application'.

FDA wants to clear passage for applications that are intended for medical usage but will not risk patients' life if it produces wrong data. That is the reason guidelines have exempted medical reference materials, medical textbook, patient information (such as calorie counter) and app with functionality of medical office.

"Mobile medical app is revolutionary aspect in healthcare industry." said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health, in a statement.

Digital healthcare industry has welcomed the guidance.

With this first step FDA has classified mobile medical app in two groups, one is harmful when app fails and another is non-harmful app even if it fails. The step is believed to be significant when world is changing rapidly. Next, FDA would probably come up with more detail guidance for the app that pose risk to one's health if it fails to work as intended.